These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35833145)

  • 1. Tacrolimus CYP3A Single-Nucleotide Polymorphisms and Preformed T- and B-Cell Alloimmune Memory Improve Current Pretransplant Rejection-Risk Stratification in Kidney Transplantation.
    Crespo E; Vidal-Alabró A; Jouve T; Fontova P; Stein M; Mocka S; Meneghini M; Sefrin A; Hruba P; Gomà M; Torija A; Donadeu L; Favà A; Cruzado JM; Melilli E; Moreso F; Viklicky O; Bemelman F; Reinke P; Grinyó J; Lloberas N; Bestard O
    Front Immunol; 2022; 13():869554. PubMed ID: 35833145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation.
    Lloberas N; Elens L; Llaudó I; Padullés A; van Gelder T; Hesselink DA; Colom H; Andreu F; Torras J; Bestard O; Cruzado JM; Gil-Vernet S; van Schaik R; Grinyó JM
    Pharmacogenet Genomics; 2017 Sep; 27(9):313-322. PubMed ID: 28704257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.
    Elens L; Bouamar R; Hesselink DA; Haufroid V; van der Heiden IP; van Gelder T; van Schaik RH
    Clin Chem; 2011 Nov; 57(11):1574-83. PubMed ID: 21903774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of CYP3A4 and CYP3A5 genetic variations on tacrolimus treatment of living-donor Egyptian kidney transplanted patients.
    Wanas H; Kamel MH; William EA; Fayad T; Abdelfattah ME; Elbadawy HM; Mikhael ES
    J Clin Lab Anal; 2023 Oct; 37(19-20):e24969. PubMed ID: 37789683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients.
    Elens L; van Schaik RH; Panin N; de Meyer M; Wallemacq P; Lison D; Mourad M; Haufroid V
    Pharmacogenomics; 2011 Oct; 12(10):1383-96. PubMed ID: 21902502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
    Staatz CE; Goodman LK; Tett SE
    Clin Pharmacokinet; 2010 Apr; 49(4):207-21. PubMed ID: 20214406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of CYP3A5 and CYP3A4 gene polymorphisms on dose requirement of calcineurin inhibitors, cyclosporine and tacrolimus, in renal allograft recipients of North India.
    Singh R; Srivastava A; Kapoor R; K Sharma R; D Mittal R
    Naunyn Schmiedebergs Arch Pharmacol; 2009 Aug; 380(2):169-77. PubMed ID: 19343327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of tacrolimus dispositional genetics on acute rejection in the first 2 weeks and estimated glomerular filtration rate in the first 3 months following kidney transplantation.
    Hu R; Barratt DT; Coller JK; Sallustio BC; Somogyi AA
    Pharmacogenet Genomics; 2019 Jan; 29(1):9-17. PubMed ID: 30489455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP3A5*3 and ABCB1 61A>G Significantly Influence Dose-adjusted Trough Blood Tacrolimus Concentrations in the First Three Months Post-Kidney Transplantation.
    Hu R; Barratt DT; Coller JK; Sallustio BC; Somogyi AA
    Basic Clin Pharmacol Toxicol; 2018 Sep; 123(3):320-326. PubMed ID: 29603629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tools for a personalized tacrolimus dose adjustment in the follow-up of renal transplant recipients. Metabolizing phenotype according to CYP3A genetic polymorphisms versus concentration-dose ratio.
    Vidal-Alabró A; Colom H; Fontova P; Cerezo G; Melilli E; Montero N; Coloma A; Manonelles A; Favà A; Cruzado JM; Torras J; Grinyó JM; Lloberas N
    Nefrologia (Engl Ed); 2024; 44(2):204-216. PubMed ID: 38614890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preformed T cell alloimmunity and HLA eplet mismatch to guide immunosuppression minimization with tacrolimus monotherapy in kidney transplantation: Results of the CELLIMIN trial.
    Bestard O; Meneghini M; Crespo E; Bemelman F; Koch M; Volk HD; Viklicky O; Giral M; Banas B; Ruiz JC; Melilli E; Hu L; van Duivenvoorden R; Nashan B; Thaiss F; Otto NM; Bold G; Stein M; Sefrin A; Lachmann N; Hruba P; Stranavova L; Brouard S; Braudeau C; Blancho G; Banas M; Irure J; Christakoudi S; Sanchez-Fueyo A; Wood KJ; Reinke P; Grinyó JM
    Am J Transplant; 2021 Aug; 21(8):2833-2845. PubMed ID: 33725408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of tacrolimus intrapatient variability and CYP3A5 polymorphism on the outcomes of pediatric kidney transplantation.
    Choi JS; Ko H; Kim HK; Chung C; Han A; Min SK; Ha J; Kang HG; Ha IS; Min S
    Pediatr Transplant; 2022 Sep; 26(6):e14297. PubMed ID: 35466485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of combined CYP3A4 and CYP3A5 single-nucleotide polymorphisms on tacrolimus exposure in kidney transplant recipients: a study according to the post-transplant phase.
    Aouam K; Kolsi A; Kerkeni E; Ben Fredj N; Chaabane A; Monastiri K; Boughattas N
    Pharmacogenomics; 2015 Dec; 16(18):2045-54. PubMed ID: 26615671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP3A5 and CYP3A4, but not ABCB1 polymorphisms affect tacrolimus dose-adjusted trough concentrations in kidney transplant recipients.
    Kurzawski M; Dąbrowska J; Dziewanowski K; Domański L; Perużyńska M; Droździk M
    Pharmacogenomics; 2014 Feb; 15(2):179-88. PubMed ID: 24444408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.
    Staatz CE; Goodman LK; Tett SE
    Clin Pharmacokinet; 2010 Mar; 49(3):141-75. PubMed ID: 20170205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines.
    Elens L; Capron A; van Schaik RH; De Meyer M; De Pauw L; Eddour DC; Latinne D; Wallemacq P; Mourad M; Haufroid V
    Ther Drug Monit; 2013 Oct; 35(5):608-16. PubMed ID: 24052064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.
    Deininger KM; Vu A; Page RL; Ambardekar AV; Lindenfeld J; Aquilante CL
    Clin Transplant; 2016 Sep; 30(9):1074-81. PubMed ID: 27314545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequencies and roles of CYP3A5, CYP3A4 and ABCB1 single nucleotide polymorphisms in Italian teenagers after kidney transplantation.
    Turolo S; Tirelli AS; Ferraresso M; Ghio L; Belingheri M; Groppali E; Torresani E; Edefonti A
    Pharmacol Rep; 2010; 62(6):1159-69. PubMed ID: 21273673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of CYP3A4 and CYP3A5 polymorphisms on tacrolimus and sirolimus exposure in stable kidney transplant recipients.
    Tamashiro EY; Felipe CR; Genvigir FDV; Rodrigues AC; Campos AB; Hirata RDC; Tedesco-Silva H; Medina-Pestana JO
    Drug Metab Pers Ther; 2017 May; 32(2):89-95. PubMed ID: 28593920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship of CYP3A5 genotype and ABCB1 diplotype to tacrolimus disposition in Brazilian kidney transplant patients.
    Cusinato DA; Lacchini R; Romao EA; Moysés-Neto M; Coelho EB
    Br J Clin Pharmacol; 2014 Aug; 78(2):364-72. PubMed ID: 24528196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.